Compounds that correct F508del-CFTR trafficking can also correct other protein trafficking diseases: an in vitro study using cell lines
Authors:
- Heidi M SampsonHSHeidi M Sampson
- Hung LamHLHung Lam
- Pei-Chun ChenPCPei-Chun Chen
- Donglei ZhangDZDonglei Zhang
- Cristina MottilloCMCristina Mottillo
- Myriam MirzaMMMyriam Mirza
- Karim QasimKQKarim Qasim
- Alvin ShrierASAlvin Shrier
- Show-Ling ShyngSSShow-Ling Shyng
- John W HanrahanJHJohn W Hanrahan
- David Y ThomasDTDavid Y Thomas
Open Access
- 14 January 2013
- journal article
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 8 (1) , 11
Abstract
Background: Many genetic diseases are due to defects in protein trafficking where the mutant protein is recognized by the quality control systems, retained in the endoplasmic reticulum (ER), and degraded by the proteasome. In many cases, the mutant protein retains function if it can be trafficked to its proper cellular location. We have identified structurally diverse correctors that restore the trafficking and function of the most common mutation causing cystic fibrosis, F508del-CFTR. Most of these correctors do not act directly as ligands of CFTR, but indirectly on other pathways to promote folding and correction. We hypothesize that these proteostasis regulators may also correct other protein trafficking diseases. Methods: To test our hypothesis, we used stable cell lines or transient transfection to express 2 well-studied trafficking disease mutations in each of 3 different proteins: the arginine-vasopressin receptor 2 (AVPR2, also known as V2R), the human ether-a-go-go-related gene (KCNH2, also known as hERG), and finally the sulfonylurea receptor 1 (ABCC8, also known as SUR1). We treated cells expressing these mutant proteins with 9 structurally diverse F508del-CFTR correctors that function through different cellular mechanisms and assessed whether correction occurred via immunoblotting and functional assays. Results were deemed significantly different from controls by a one-way ANOVA (p < 0.05). Results: Here we show that F508del-CFTR correctors RDR1, KM60 and KM57 also correct some mutant alleles of other protein trafficking diseases. We also show that one corrector, the cardiac glycoside ouabain, was found to alter the glycosylation of all mutant alleles tested. Conclusions: Correctors of F508del-CFTR trafficking might have broader applications to other protein trafficking diseases.Keywords
This publication has 39 references indexed in Scilit:
- Correctors of Protein Trafficking Defects Identified by a Novel High‐Throughput Screening AssayChemBioChem, 2007
- Pyrimethamine as a Potential Pharmacological Chaperone for Late-onset Forms of GM2 GangliosidosisJournal of Biological Chemistry, 2007
- Rescue of ΔF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small moleculesAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2006
- Pharmacological Enhancement of β-Hexosaminidase Activity in Fibroblasts from Adult Tay-Sachs and Sandhoff PatientsJournal of Biological Chemistry, 2004
- Chemical chaperones increase the cellular activity of N370S β-glucosidase: A therapeutic strategy for Gaucher diseaseProceedings of the National Academy of Sciences, 2002
- In vitro inhibition and intracellular enhancement of lysosomal α‐galactosidase A activity in Fabry lymphoblasts by 1‐deoxygalactonojirimycin and its derivativesEuropean Journal of Biochemistry, 2000
- Accelerated transport and maturation of lysosomal α–galactosidase A in Fabry lymphoblasts by an enzyme inhibitorNature Medicine, 1999
- In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing delta F508-CFTR.Journal of Clinical Investigation, 1997
- Chemical chaperones correct the mutant phenotype of the ΔF508 cystic fibrosis transmembrane conductance regulator proteinCell Stress and Chaperones, 1996
- Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitiveNature, 1992